What is the clinical evidence from this study?

Study design: Review. Population: End-stage renal disease and hypertension. Intervention: Aldosterone receptor blockade.

What question did this study set out to answer?

To evaluate the mechanistic role of aldosterone as an independent driver of progressive renal dysfunction and vascular injury in hypertensive kidney disease.

May 1, 2001Journal of Hypertension

Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift

View Full Paper

Ask AI

Bookmark

Key result

Experimental evidence suggests aldosterone is an important pathogenetic factor in progressive renal disease, promoting fibrosis and proteinuria independent of renin-angiotensin blockade.

Why the study?

Does aldosterone receptor blockade prevent progressive renal dysfunction in hypertension?

Population

Hypertensive patients at risk for progressive renal disease (based on experimental rat models)

Design

Review

Authors

MEMurray EpsteinUniversity of Miami

Discussion

Member takes

Implication

Supports trials of aldosterone blockade for renal protection in hypertension; leaves open clinical efficacy beyond ACEi/ARB.

Key Points

To evaluate the mechanistic role of aldosterone as an independent driver of progressive renal dysfunction and vascular injury in hypertensive kidney disease.
Synthesized findings from preclinical hypertensive and subtotal nephrectomy rat models assessing renal structural damage and proteinuria.
Evaluated therapeutic effects of selective aldosterone blockade, renin-angiotensin system inhibition, and exogenous aldosterone reinfusion.
Selective aldosterone blockade reduces proteinuria, nephrosclerosis, and glomerulosclerosis independently of upstream renin-angiotensin system inhibition.
Exogenous aldosterone reinfusion restores proteinuria and renal tissue damage despite ongoing pharmacological blockade with ACE inhibitors or ARBs.
Aldosterone promotes renal fibrosis through elevated plasminogen activator inhibitor-1 expression, transforming growth factor-beta 1 stimulation, and reactive oxygen species generation.

Structured PICO

Does aldosterone receptor blockade prevent progressive renal dysfunction in hypertension?

Population

Hypertensive patients at risk for progressive renal disease (based on experimental rat models)

Intervention

Aldosterone receptor blockade

Outcome

Reduction in proteinuria and nephrosclerosis/glomerulosclerosissurrogate

Experimental evidence suggests aldosterone is an important pathogenetic factor in progressive renal disease, providing a rationale for clinical trials of aldosterone receptor blockade for renal protection.

Cite This Study

Murray Epstein (2001) conducted a review in End-stage renal disease and hypertension. Aldosterone receptor blockade was evaluated. Experimental evidence suggests aldosterone is an important pathogenetic factor in progressive renal disease, promoting fibrosis and proteinuria independent of renin-angiotensin blockade.

synapsesocial.com/papers/6a1564775347fbb1739fb592 https://doi.org/10.1097/00004872-200105000-00001

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider